144 related articles for article (PubMed ID: 3449204)
1. In vitro and in vivo characterization of 2,6-dimethyl-3,5-dicarbomethoxy-4-(2-isothiocyano)phenyl-1,4- dihydropy ridine as a Ca2+ channel antagonist.
Gengo P; Su CM; Yousif FB; Triggle DJ
Can J Physiol Pharmacol; 1987 Dec; 65(12):2472-82. PubMed ID: 3449204
[TBL] [Abstract][Full Text] [Related]
2. o-Isothiocyanate dihydropyridine (oNCS-DHP), a long-acting, reversible inhibitor of the Ca++ channel.
Kozlowski R; Ehrhard P; Fischli W; Osterrieder W; Holck M
J Pharmacol Exp Ther; 1986 Sep; 238(3):1084-91. PubMed ID: 2427686
[TBL] [Abstract][Full Text] [Related]
3. Effects of a new dihydropyridine calcium antagonist on vascular smooth muscles, cardiac muscles and [3H]-nitrendipine binding.
Miura A; Ukai Y; Matsuzaki T; Taniguchi N; Hayashi S; Kano S; Kimura Y; Kimura K; Enomoto H
Arzneimittelforschung; 1986 Sep; 36(9):1323-8. PubMed ID: 3790181
[TBL] [Abstract][Full Text] [Related]
4. Ca2+ channel antagonist actions in bladder smooth muscle: comparative pharmacologic and [3H]nitrendipine binding studies.
Yousif FB; Bolger GT; Ruzycky A; Triggle DJ
Can J Physiol Pharmacol; 1985 May; 63(5):453-62. PubMed ID: 2994869
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological in vitro studies of the new 1,4-dihydropyridine calcium antagonist lercanidipine.
Guarneri L; Angelico P; Ibba M; Poggesi E; Taddei C; Leonardi A; Testa R
Arzneimittelforschung; 1996 Jan; 46(1):15-24. PubMed ID: 8821512
[TBL] [Abstract][Full Text] [Related]
6. Effects of dihydropyridine calcium channel blocking drugs on rat brain muscarinic and alpha-adrenergic receptors.
Thayer SA; Welcome M; Chhabra A; Fairhurst AS
Biochem Pharmacol; 1985 Jan; 34(2):175-80. PubMed ID: 2981533
[TBL] [Abstract][Full Text] [Related]
7. Interaction of phenoxybenzamine with muscarinic receptors and calcium channels.
Gengo PJ; Yousif F; Janis RA; Triggle DJ
Biochem Pharmacol; 1984 Nov; 33(21):3445-9. PubMed ID: 6093812
[TBL] [Abstract][Full Text] [Related]
8. Pharmacologic and radioligand binding analysis of the actions of 1,4-dihydropyridine activators related to Bay K 8644 in smooth muscle, cardiac muscle and neuronal preparations.
Kwon YW; Franckowiak G; Langs DA; Hawthorn M; Joslyn A; Triggle DJ
Naunyn Schmiedebergs Arch Pharmacol; 1989; 339(1-2):19-30. PubMed ID: 2471085
[TBL] [Abstract][Full Text] [Related]
9. Pharmacologic and radioligand binding analysis of the actions of 1,4-dihydropyridine activator-antagonist pairs in smooth muscle.
Wei XY; Luchowski EM; Rutledge A; Su CM; Triggle DJ
J Pharmacol Exp Ther; 1986 Oct; 239(1):144-53. PubMed ID: 2428971
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the effects of AHN 086, an irreversible ligand of "peripheral" benzodiazepine receptors, on contraction in guinea-pig atrial and ileal longitudinal smooth muscle.
Bolger GT; Newman AH; Rice KC; Lueddens HW; Basile AS; Skolnick P
Can J Physiol Pharmacol; 1989 Feb; 67(2):126-34. PubMed ID: 2469529
[TBL] [Abstract][Full Text] [Related]
11. Photoaffinity labelling of the cardiac calcium channel. (-)-[3H]azidopine labels a 165 kDa polypeptide, and evidence against a [3H]-1,4-dihydropyridine-isothiocyanate being a calcium-channel-specific affinity ligand.
Ferry DR; Goll A; Glossmann H
Biochem J; 1987 Apr; 243(1):127-35. PubMed ID: 2440422
[TBL] [Abstract][Full Text] [Related]
12. The interactions of 1,4-dihydropyridines bearing a 2-(2-aminoethylthio)methyl substituent at voltage-dependent Ca2+ channels of smooth muscle, cardiac muscle and neuronal tissues.
Kwon YW; Zhong Q; Wei XY; Zheng W; Triggle DJ
Naunyn Schmiedebergs Arch Pharmacol; 1990; 341(1-2):128-36. PubMed ID: 2156174
[TBL] [Abstract][Full Text] [Related]
13. Identification of a novel calcium antagonist binding site in rat brain by SR 33557.
Kenny BA; Fraser S; Spedding M
Br J Pharmacol; 1993 Jan; 108(1):93-9. PubMed ID: 7679034
[TBL] [Abstract][Full Text] [Related]
14. Calcium channel blocking and vasodilating actions of the novel dihydropyridine derivative AE0047.
Nishikawa M; Gohda M; Shinyama H; Matzno S; Yamanaga K; Kido H; Nakamura N
Clin Exp Pharmacol Physiol; 1998 May; 25(5):347-54. PubMed ID: 9612662
[TBL] [Abstract][Full Text] [Related]
15. (+)-S-12967 and (-)-S-12968: 1,4-dihydropyridine stereoisomers with calcium channel agonistic and antagonistic properties in rat resistance arteries.
Prieto D; Mulvany MJ; Nyborg NC
Br J Pharmacol; 1991 Jul; 103(3):1703-8. PubMed ID: 1933134
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory actions of a series of Ca2+ channel antagonists against agonist and K+ depolarization induced responses in smooth muscle: an assessment of selectivity of action.
Yousif FB; Triggle DJ
Can J Physiol Pharmacol; 1986 Mar; 64(3):273-83. PubMed ID: 2423216
[TBL] [Abstract][Full Text] [Related]
17. MPC-1304, another type of dihydropyridine, possessing highly potent vasodilating action.
Miyoshi K; Kanda A; Miyake H; Ichihara K; Kamei H; Nagasaka M
Eur J Pharmacol; 1993 Jul; 238(2-3):139-48. PubMed ID: 7691619
[TBL] [Abstract][Full Text] [Related]
18. Activation of L-type calcium channel by tolazoline derivatives: role of isothiocyanate moiety.
Lei L; Vaghy PL; Slavica M; De Los Angeles J; Smith B; Miller DD; Feller DR
J Cardiovasc Pharmacol; 1998 May; 31(5):721-33. PubMed ID: 9593072
[TBL] [Abstract][Full Text] [Related]
19. Lacidipine: a calcium antagonist with potent and long-lasting antihypertensive effects in animal studies.
Micheli D; Collodel A; Semeraro C; Gaviraghi G; Carpi C
J Cardiovasc Pharmacol; 1990 Apr; 15(4):666-75. PubMed ID: 1691398
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological profiles of YM-16151-1 and its optical isomers: a novel calcium entry blocking and selective beta-1 adrenoceptor blocking agent.
Asano M; Uchida W; Shibasaki K; Terai M; Inagaki O; Takenaka T; Matsumoto Y; Fujikura T
J Pharmacol Exp Ther; 1990 Jul; 254(1):204-11. PubMed ID: 1973196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
